A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2800 participants.

Also called NCT07624305

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,800 participants (planned count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07624305
  • EU CT 2026-526114-90-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Austria, Brazil, Bulgaria, Canada, China, France, Germany, Greece, India, Italy, Japan, Malaysia, Mexico, Peru, Philippines, Poland, Romania, South Korea, Spain, Taiwan, Thailand, Türkiye, Ukraine, United Kingdom, Vietnam (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07624305. Randomized; quadruple masking; primary purpose treatment. Start 2026-09-01 (actual); primary completion 2030-07-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
Condition
Renal Insufficiency, Chronic
Intervention (Drug)
Balcinrenone/dapagliflozin
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Placebo matching Dapagliflozin
Intervention (Drug)
Placebo matching balcinrenone/dapagliflozin
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct07624305
Content hash
5d9fa1316a5de506620958201e04c5d42b1930ddd49b86d411db9185c7e1f6bb